Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis

被引:24
作者
Castell, DO
Kahrilas, PJ
Richter, JE
Vakil, NB
Johnson, DA
Zuckerman, S
Skammer, W
Levine, JG
机构
[1] Med Univ S Carolina, Dept Gastroenterol & Hepatol, Charleston, SC 29425 USA
[2] Northwestern Univ, Sch Med, Div Gastroenterol & Hepatol, Chicago, IL USA
[3] Cleveland Clin Fdn, Dept Gastroenterol, Cleveland, OH 44195 USA
[4] Univ Wisconsin, Sch Med, Div Gastroenterol, Milwaukee, WI 53201 USA
[5] Eastern Virginia Med Sch, Div Gastroenterol, Norfolk, VA 23501 USA
[6] AstraZeneca, Wayne, PA USA
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVES: Esomeprazole, the S isomer of omeprazole, has been shown to have higher healing rates of erosive esophagitis than omeprazole. This study compared esomeprazole with lansoprazole for the healing of erosive esophagitis and resolution of heartburn. METHODS: This United States multicenter, randomized, double blind, parallel group trial was performed in 5241 adult patients (intent-to-treat population) with endoscopically documented erosive esophagitis, which was graded by severity at baseline (Los Angeles classification). Patients received 40 mg of esomeprazole (n = 2624) or 30 mg of lansoprazole (n = 2617) once daily before breakfast for up to 8 wk. The primary efficacy endpoint was heating of erosive esophagitis at week 8. Secondary assessments included proportion of patients healed at week 4, resolution of investigator-recorded heartburn, time to first and time to sustained resolution of patient diary-recorded heartburn, and proportion of heartburn-free days and nights. RESULTS: Esomeprazole (40 mg) demonstrated significantly higher healing rates (92.6%, 95% CI = 91.5-93.6%) than lansoprazole (30 mg) (88.8%, 95% CI = 87.5-90.0%) at week 8 (p = 0.0001, life-table estimates, intent-to-treat analysis). A significant difference in healing rates favoring esomeprazole was also observed at week 4. The difference in healing rates between esomeprazole and lansoprazole increased as baseline severity of erosive esophagitis increased. Sustained resolution of heartburn occurred faster and in more patients treated with esomeprazole. Sustained resolution of nocturnal heartburn also occurred faster with esomeprazole. Both treatments were well tolerated. CONCLUSIONS: Esomeprazole (40 mg) is more effective than lansoprazole (30 mg) in healing erosive esophagitis and resolving heartburn. Healing rates are consistently high with esomeprazole, irrespective of baseline disease severity. (Am J Gastroenterol 2002;97:575-583. (C) 2002 by Am. Coll. of Gastroenterology).
引用
收藏
页码:575 / 583
页数:9
相关论文
共 33 条
[1]   Pharmacokinetics, metabolism and interactions of acid pump inhibitors - Focus on omeprazole, lansoprazole and pantoprazole [J].
Andersson, T .
CLINICAL PHARMACOKINETICS, 1996, 31 (01) :9-28
[2]   The endoscopic assessment of esophagitis: A progress report on observer agreement [J].
Armstrong, D ;
Bennett, JR ;
Blum, AL ;
Dent, J ;
deDombal, FT ;
Galmiche, JP ;
Lundell, L ;
Margulies, M ;
Richter, JE ;
Spechler, SJ ;
Tytgat, GNJ ;
Wallin, L .
GASTROENTEROLOGY, 1996, 111 (01) :85-92
[3]  
BARDHAN KD, 1995, ALIMENT PHARM THERAP, V9, P145
[4]  
Castell DO, 1996, AM J GASTROENTEROL, V91, P1749
[5]  
Chiba N, 1997, Can J Gastroenterol, V11 Suppl B, p66B
[6]  
Corinaldesi R, 1995, ALIMENT PHARM THERAP, V9, P667
[7]  
Dekkers CPM, 1999, ALIMENT PHARM THERAP, V13, P49
[8]  
Delchier JC, 2000, SCAND J GASTROENTERO, V35, P1245
[9]   First comparison pantoprazole versus lansoprazole in hospital and private practice patients with reflux esophagitis. [J].
Dupas, JL ;
Houcke, P ;
Giret-d'Orsay, G ;
Samoyeau, R .
GASTROENTEROLOGY, 1998, 114 (04) :A110-A111
[10]   The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment - Suggested disease management guidelines [J].
Fennerty, MB ;
Castell, D ;
Fendrick, AM ;
Halpern, M ;
Johnson, D ;
Kahrilas, PJ ;
Lieberman, D ;
Richter, JE ;
Sampliner, RE .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (05) :477-484